Real-World Phosphate Binder Use Described
Nearly two-thirds of patients receiving dialysis use phosphate binders intermittently, a study found.
Diagnosis & Disease Information
RCT Data Needed on Phosphate-Lowering Agents and NDD-CKD Outcomes
Systematic reviews on this topic have largely been focused on patients receiving dialysis.
Phosphate Binder Dissatisfaction May Affect Patient Outcomes
Dissatisfaction with taking phosphate binders may influence medication adherence and ultimately clinical outcomes, according to investigators.
Tenapanor Monotherapy May Reduce Phosphorus Levels in Patients on Dialysis
Full results from the OPTIMIZE study, due to be completed in August 2021, are forthcoming.
Tenapanor Reduces Phosphate Binder Pill Burden in Hemodialysis
Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine.
Non-Calcium Phosphate Binder May Not Further Reduce Cardiovascular Events
Trial investigated lanthanum carbonate, which has been used worldwide to treat hyperphosphatemia and has been reported to delay vascular calcification.
Phosphate Binders May Have Other Gastrointestinal Effects
According to preliminary research, phosphate binders may bind to helpful substances such as vitamin K, but also to harmful ones, such as lipopolysaccharides and advanced glycation end products.
Iron-Based Binder Improves Phosphorus, FGF-23, and Anemia
Clinicians were able to reduce doses of erythropoiesis-stimulating agents and intravenous iron.
Non-Calcium Phosphate Binders May Reduce FGF-23
Median intact FGF-23 significantly fell by 64% over 1 year of treatment with sucroferic oxyhydroxide or sevelamer.
Nicotinic Acid May Improve Hyperphosphatemia in HD
Meta-analysis shows that nicotinic acid could be a good alternative or add on to traditional phosphate binders, but it is associated with a high rate of adverse events.
- Loading...
Loading...
Next post in Hyperphosphatemia
Loading... 
Loading...